Pacira BioSciences, Inc.
PCRX· Nasdaq
Released Nov 2, 2023, before the open
10-Q filed Nov 2, 2023, 33 days after period end · 0001396814-23-000079
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $163.93M | $167.47M | $127.72M | $117.48M |
| Net Income | $10.86M | -$693.00K | $17.66M | $130.12M |
| EPS Diluted |
Pacira BioSciences, Inc. · CIK 1396814 · Engraved from SEC EDGAR
| $0.23 |
| -$0.02 |
| $0.39 |
| $2.94 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.